Bosentan therapy for pulmonary arterial hypertension

The New England Journal of Medicine
Lewis J RubinGerald Simonneau

Abstract

Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses. In this double-blind, placebo-controlled study, we randomly assigned 213 patients with pulmonary arterial hypertension (primary or associated with connective-tissue disease) to receive placebo or to receive 62.5 mg of bosentan twice daily for 4 weeks followed by either of two doses of bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. The primary end point was the degree of change in exercise capacity. Secondary end points included the change in the Borg dyspnea index, the change in the World Health Organization (WHO) functional class, and the time to clinical worsening. At week 16, patients treated with bosentan had an improved six-minute walking distance; the mean difference between the placebo group and the combined bosentan groups was 44 m (95 percent confidence interval, 21 to 67; P<0.001). Bosentan also improved the...Continue Reading

References

Apr 1, 1986·Arthritis and Rheumatism·A M StupiT A Medsger
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
Jan 9, 1997·The New England Journal of Medicine·L J Rubin
Jan 27, 1999·Pulmonary Pharmacology & Therapeutics·M R MacLean
Nov 24, 1999·Circulation·C SchmidH H Scheld
Aug 11, 2000·European Journal of Heart Failure·P Mylona, J G Cleland

❮ Previous
Next ❯

Citations

Nov 1, 2002·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Myung H ParkMandeep R Mehra
Dec 2, 2009·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·M C PostR J Snijder
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Nazzareno GalièAngelo Branzi
Sep 18, 2010·Cellular and Molecular Life Sciences : CMLS·Yoshifumi Kawanabe, Surya M Nauli
Sep 12, 2006·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·C Sunderkötter, G Riemekasten
Feb 11, 2005·Der Internist·H OlschewskiW Seeger
Aug 26, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Maria E CampianHanno L Tan
Nov 28, 2007·European Journal of Clinical Pharmacology·Gary BurgessJasper Dingemanse
Jun 12, 2013·European Journal of Clinical Pharmacology·Christoph MarkertWalter E Haefeli
Mar 31, 2011·Pediatric Cardiology·Shinichi TakatsukiDavid Dunbar Ivy
Feb 22, 2012·Pediatric Cardiology·Song I YangDeok Young Choi
Dec 20, 2007·Rheumatology International·Sara SimeoniClaudio Lunardi
Sep 27, 2012·Rheumatology International·Afsha A Topal, Rachita S Dhurat
Feb 13, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Ralf EwertStephan B Felix
May 1, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Horst OlschewskiH Worth
May 31, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Stephan Rosenkranz
Dec 6, 2005·Zeitschrift für Rheumatologie·H SchotteM Gaubitz
Mar 29, 2005·Zeitschrift für Rheumatologie·G Riemekasten, H Schulze-Koops
Jul 14, 2009·Zeitschrift für Rheumatologie·M ClaussenM M Hoeper
Oct 17, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Kevin E C Meyers, Christine Sethna
Oct 19, 2006·Journal of Gastroenterology·Michael HalankGert Hoeffken
Jan 29, 2011·Clinical Rheumatology·Yavuz PehlivanTaner Babacan
Mar 23, 2013·Annals of Biomedical Engineering·Lauren D C CasaAjit P Yoganathan
Jan 26, 2006·Journal of Inherited Metabolic Disease·A R BarclayM O Stormon
Nov 25, 2006·Cardiovascular Drugs and Therapy·Makoto SaharaRyozo Nagai
Feb 21, 2009·Current Atherosclerosis Reports·Aydin Uzunpinar, Mehmet Cilingiroglu
Jan 27, 2009·Current Gastroenterology Reports·Ravi P NayakGeorge M Matuschak
Mar 19, 2003·Current Hypertension Reports·Marc Iglarz, Ernesto L Schiffrin
Apr 8, 2006·Current Hypertension Reports·Gabriel VorobiofJohn D Bisognano
Oct 15, 2013·Current Hypertension Reports·Yan WuMarc Humbert
Oct 29, 2013·Current Hypertension Reports·Dan-Chen WuZhi-Cheng Jing
Oct 22, 2004·Current Treatment Options in Cardiovascular Medicine·Mark D Huffman, Vallerie V McLaughlin
Jan 25, 2012·Cardiovascular Toxicology·Paulino A AlvarezManuel Vazquez Blanco
Dec 11, 2008·Clinical Reviews in Allergy & Immunology·Fredrick M Wigley
Jan 10, 2009·Clinical Reviews in Allergy & Immunology·Vasiliki Kalliopi K BourniaM Eric Gershwin
May 27, 2006·Cardiology in the Young·Eugene KotlyarDavid S Celermajer
Apr 25, 2007·Cardiology in the Young·Henrik BrunHenrik Holmstrom

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

American Journal of Respiratory and Critical Care Medicine
Robyn J BarstSTRIDE-1 Study Group
The New England Journal of Medicine
Horst OlschewskiAerosolized Iloprost Randomized Study Group
© 2022 Meta ULC. All rights reserved